A share price of Arcus Biosciences Inc [RCUS] is currently trading at $18.21, up 9.37%. An important factor to consider is whether the stock is rising or falling in short-term value. The RCUS shares have gain 4.12% over the last week, with a monthly amount drifted -9.76%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, Arcus Biosciences Announces New Employment Inducement Grants. In a post published today on Yahoo Finance, Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and restricted stock units to acquire a total of 9,200 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on November 18, 2022, when BofA Securities initiated its Neutral rating and assigned the stock a price target of $33. Previously, Morgan Stanley started tracking the stock with Overweight rating on October 11, 2022, and set its price target to $40. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $50 on November 24, 2020. Evercore ISI initiated its recommendation with a Outperform. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 03, 2020, and assigned it a price target of $21. In a note dated March 04, 2020, Barclays initiated an Overweight rating and provided a target price of $24 on this stock.
Arcus Biosciences Inc experienced fluctuations in its stock price throughout the past year between $12.95 and $25.47. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $18.21 at the most recent close of the market. An investor can expect a potential return of 130.64% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Trailing Twelve Months sales for Arcus Biosciences Inc [NYSE:RCUS] were 117.00M which represents -7.89% decline. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -2.91%, Pretax Profit Margin comes in at -2.57%, and Net Profit Margin reading is -2.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.57 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.05 points at the first support level, and at 15.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.95, and for the 2nd resistance point, it is at 19.70.
Arcus Biosciences Inc [RCUS] reported earnings per share of -$1.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.02/share, meaning a difference of -$0.06 and a surprise factor of -5.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.94 per share as compared to estimates of -$1.13 per share, a difference of $0.19 representing a surprise of 16.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcus Biosciences Inc [NYSE:RCUS] is 4.52. On the other hand, the Quick Ratio is 4.52, and the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 14.14, the price to book ratio is 2.98.
Transactions by insiders
Recent insider trading involved Jarrett Jennifer, Chief Operating Officer, that happened on Mar 18 ’24 when 13449.0 shares were sold. Chief Operating Officer, Jarrett Jennifer completed a deal on Feb 27 ’24 to sell 34070.0 shares. Meanwhile, President Jaen Juan C. sold 23132.0 shares on Feb 27 ’24.
